Premarket Gainer
PHGE Biomx6.65+0.08+1.1%
Premarket:8.25+1.60 (+24.1%)
BiomX Announces Positive Results of a Phase 1a Pharmacokinetic Study for Inflammatory Bowel Disease/Primary Sclerosing Cholangitis (IBD/PSC) Evaluating Delivery of Oral BX002 Phage Therapy
Business WireTue, 2-Feb 6:30 AM
PHGE Biomx Inc.7.72+0.23+3.1%
Premarket:9.50+1.78 (+23.1%)
BiomX Announces Positive Topline Data from Phase 1 Study for Lead Candidate BX001 for Acne-Prone Skin
Business WireTue, 31-Mar 6:30 AM
